自引率: 暂无数据
被引量: 744
通过率: 暂无数据
审稿周期: 1.33
版面费用: 暂无数据
国人发稿量: 4
投稿须知/期刊简介:
Each bimonthly issue of Current Problems in Cancer presents a single-topic, in-depth discussion, usually focused on the integrated management of a particular type of cancer or on a problem faced in a wide variety of malignancies. Issues may explore a particular category of drugs, an emerging interventional technique, or rehabilitation/reconstruction. Extensive bibliographies allow readers to easily locate additional information on related topics. Current Problems in Cancer serves the wide spectrum of physicians who treat patients with neoplastic disease.
期刊描述简介:
Each bimonthly issue of Current Problems in Cancer presents a single-topic, in-depth discussion, usually focused on the integrated management of a particular type of cancer or on a problem faced in a wide variety of malignancies. Issues may explore a particular category of drugs, an emerging interventional technique, or rehabilitation/reconstruction. Extensive bibliographies allow readers to easily locate additional information on related topics. Current Problems in Cancer serves the wide spectrum of physicians who treat patients with neoplastic disease.
-
Four versus six cycles of platinum-based chemotherapy for advanced Urothelial carcinoma in the era of immune checkpoint inhibitors: A retrospective cohort study (FOCUS, KCSG-GU23-08).
被引量：- 发表：1970
-
Metaplastic breast cancer: Experience with ifosfamide based chemotherapy.
被引量：- 发表：1970
-
Mapping the intricacies of GLI1 in hedgehog signaling: A combined bioinformatics and clinical analysis in Head & Neck cancer in Western India.
被引量：- 发表：1970
-
ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals.
Rearrangements involving the ROS1 gene are infrequent in non-small cell lung cancer (NSCLC) but represent an important targetable driver alteration. Occurring most commonly in patients with adenocarcinoma who have a light or never smoking history, ROS1 rearrangements can be identified by either fluorescence in-situ hybridization (FISH) or next-generation sequencing techniques. Multiple tyrosine kinase inhibitors (TKIs) are now available for the effective treatment of ROS1-rearranged NSCLC in the metastatic setting including crizotinib, entrectinib, and repotrectinib as first-line therapy options. In addition, newer targeted therapies with increased selectivity for ROS1 over other targets are also emerging. As treatment of the disease continues to evolve, understanding the clinical course of patients with ROS1-rearranged NSCLC as well as the data supporting the latest therapy options is key to timely, effective, and longitudinal care.
被引量：- 发表：1970
-
Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies.
Advancements in somatostatin receptor (SSTR) targeted imaging and treatment of well-differentiated neuroendocrine tumors (NETs) have revolutionized the management of these tumors. This comprehensive review delves into the current practice, discussing the use of the various FDA-approved SSTR-agonist PET tracers and the predictive imaging biomarkers, and elaborating on Lu177-DOTATATE peptide receptor radionuclide therapy (PRRT) including the evolving areas of post-therapy imaging practices, PRRT retreatment, and the potential role of dosimetry in optimizing patient treatments. The future directions sections highlight ongoing research on investigational PET imaging radiotracers, future prospects in alpha particle therapy, and combination therapy strategies.
被引量：- 发表：1970
